Fresenius Kabi launches ready to administer Neostigmine methylsulfate injection
Fresenius Kabi is debuting a new addition to its Simplist line of ready-to-administer prefilled syringes. The company recently launched neostigmine methylsulfate injection, in 3 mg/3 ml Simplist syringes.
The Fresenius Kabi Simplist neostigmine injection prefilled syringe is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market, the company said.
Fresenius Kabi has sold neostigmine injection, in 0.5 mg/ml and 1 mg/ml vial presentations since 2015.
“Fresenius Kabi is pleased to continue the expansion of our convenient Simplist prefilled syringe portfolio,” Fresenius Kabi USA president and CEO John Ducker said. “This is the fourth Simplist product we’ve introduced this year and represents the strength of our pipeline of important therapies and delivery systems that can help physicians practice more efficiently.”
Neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for intravenous use for reversal of the effects of nondepolarizing neuromuscular blocking agents after surgery.
The Fresenius Kabi Simplist neostigmine injection prefilled syringe is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market, the company said.
Fresenius Kabi has sold neostigmine injection, in 0.5 mg/ml and 1 mg/ml vial presentations since 2015.
“Fresenius Kabi is pleased to continue the expansion of our convenient Simplist prefilled syringe portfolio,” Fresenius Kabi USA president and CEO John Ducker said. “This is the fourth Simplist product we’ve introduced this year and represents the strength of our pipeline of important therapies and delivery systems that can help physicians practice more efficiently.”
Neostigmine methylsulfate injection, a cholinesterase inhibitor, is indicated for intravenous use for reversal of the effects of nondepolarizing neuromuscular blocking agents after surgery.